Press Release: Cancellation of publicly held Actelion shares and delisting from SIX Swiss Exchange as of November 7, 2017

Actelion Pharmaceuticals Ltd / Cancellation of publicly held Actelion

shares and delisting from SIX Swiss Exchange as of November 7, 2017.

Processed and transmitted by Nasdaq Corporate Solutions. The issuer is

solely responsible for the content of this announcement.

ALLSCHWIL/BASEL, SWITZERLAND - October 31, 2017 - By decision dated

October 25, 2017, the Cantonal Court of the Canton of Basel-Landschaft

cancelled all publicly held registered shares of Actelion Ltd (Actelion)

with a nominal value of CHF 0.50 each (the Actelion Shares) based on

article 137 of the Federal Act on Financial Market Infrastructures and

Market Conduct in Securities and Derivatives Trading (Financial Market

Infrastructure Act).

The holders of the cancelled Actelion Shares will be paid a cash

compensation in the amount of USD 280 for each cancelled Actelion Share,

corresponding to the offer price paid by Janssen Holding GmbH, an

indirect subsidiary of Johnson & Johnson, in its public tender offer for

all publicly held Actelion Shares. The settlement and payment of the

compensation to the remaining minority shareholders of Actelion will

take place on or around November 10, 2017.

By decision dated April 18, 2017, SIX Exchange Regulation approved the

delisting of the Actelion Shares from SIX Swiss Exchange. By decision

dated October 30, 2017, SIX Exchange Regulation determined that the last

day of trading of the Actelion Shares will be November 6, 2017 and that

the Actelion Shares will be delisted from SIX Swiss Exchange on November

7, 2017.

###

NOTES TO EDITORS

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the

people of Johnson & Johnson. We embrace research and science - bringing

innovative ideas, products and services to advance the health and

well-being of people. Our approximately 130,800 employees at more than

250 Johnson & Johnson operating companies work with partners in health

care to touch the lives of over a billion people every day, throughout

the world.

About the Janssen Pharmaceutical Companies of Johnson & Johnson

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are

working to create a world without disease. Transforming lives by finding

new and better ways to prevent, intercept, treat and cure disease

inspires us. We bring together the best minds and pursue the most

promising science. We are Janssen. We collaborate with the world for the

health of everyone in it. Learn more at www.janssen.com. Follow us at

www.twitter.com/JanssenUS and www.twitter.com/JanssenGlobal.

About Actelion Ltd

In June 2017, Actelion became part of the Janssen Pharmaceutical

Companies of Johnson & Johnson. Actelion's medicines help expand and

strengthen Janssen's portfolio with leading, differentiated in-market

medicines and promising late-stage compounds. Janssen has added

Pulmonary Hypertension as a therapeutic area of focus to maintain the

leadership position Actelion has built in this important disease area.

For further information please contact:

Investor Relations - Actelion Pharmaceuticals Ltd

+41 61 565 6565

www.actelion.com

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking statements" as defined in

the Private Securities Litigation Reform Act of 1995 regarding the

acquisition of Actelion Ltd. The reader is cautioned not to rely on

these forward-looking statements. These statements are based on current

expectations of future events. If underlying assumptions prove

inaccurate or known or unknown risks or uncertainties materialize,

actual results could vary materially from the expectations and

projections of Johnson & Johnson. Risks and uncertainties include, but

are not limited to: risks and uncertainties related to the ability of

the Johnson & Johnson family of companies to successfully integrate the

products, employees/operations and clinical work of Actelion, as well as

the ability to ensure continued performance or market growth of

Actelion's products; the potential that the expected benefits and

opportunities of the transaction may not be realized or may take longer

to realize than expected; challenges inherent in product research and

development, including the uncertainty of clinical success and obtaining

regulatory approvals; uncertainty of commercial success for new and

existing products; competition, including technological advances, new

products and patents attained by competitors; adverse litigation or

government action; challenges to patents; changes to applicable laws and

regulations, including domestic and foreign health care reforms; changes

in behavior and spending patterns or financial distress of purchasers of

health care products and services; manufacturing difficulties and

delays; product efficacy or safety concerns resulting in product recalls

or regulatory action; and trends toward health care cost containment. A

further list and description of these risks, uncertainties and other

factors and the general risks associated with the respective businesses

of Johnson & Johnson and Actelion can be found in Johnson & Johnson's

publicly available filings with the U.S. Securities and Exchange

Commission, and Actelion's publicly available filings on its website.

Copies of these filings, as well as subsequent filings, are available

online at www.sec.gov, www.jnj.com, www.actelion.com or on request from

Johnson & Johnson. Johnson & Johnson does not undertake to update any

forward-looking statement as a result of new information or future

events or developments.

Press Release PDF : http://hugin.info/131801/R/2145789/822634.pdf

This announcement is distributed by Nasdaq Corporate Solutions on behalf

of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely

responsible for the content, accuracy and originality of the information

contained therein.

Source: Actelion Pharmaceuticals Ltd via Globenewswire

--- End of Message ---

Actelion Pharmaceuticals Ltd

Gewerbestrasse 16 Allschwil Switzerland

ISIN: CH0010532478;

http://www.actelion.com

(END) Dow Jones Newswires

October 31, 2017 02:00 ET (06:00 GMT)